Patent classifications
C07K1/20
METHOD FOR PREPARING RECOMBINANT HUMAN NERVE GROWTH FACTOR
Provided is a method for preparing a recombinant human nerve growth factor, which can be used as a therapeutic drug.
METHOD FOR PREPARING RECOMBINANT HUMAN NERVE GROWTH FACTOR
Provided is a method for preparing a recombinant human nerve growth factor, which can be used as a therapeutic drug.
ISARIDIN CYCLODEPSIPEPTIDE DERIVATIVES, AND PREPARATION AND APPLICATION THEREOF
Provided herein are an isaridin cyclodepsipeptide derivative, and a preparation and an application thereof. The isaridin cyclodepsipeptide derivative is shown in formula (I), and is isolated from ascidian-associated fungi.
##STR00001##
ISARIDIN CYCLODEPSIPEPTIDE DERIVATIVES, AND PREPARATION AND APPLICATION THEREOF
Provided herein are an isaridin cyclodepsipeptide derivative, and a preparation and an application thereof. The isaridin cyclodepsipeptide derivative is shown in formula (I), and is isolated from ascidian-associated fungi.
##STR00001##
ON-LINE ULTRA PERFORMANCE HYDROPHOBIC INTERACTION CHROMATOGRAPHY FOR MONITORING AT LEAST ONE PRODUCT ATTRIBUTE
The present invention relates to a method of measuring at least one product quality attributes, including critical quality attributes (e.g., oxidation, C-terminal lysine, aggregation, N-terminal glutamine cyclization.) by an online liquid chromatography system, wherein the liquid chromatography system is running a hydrophobic interaction chromatography (HIC) method.
PURIFICATION METHOD FOR IMIDAZOLE DIPEPTIDES
The objective of the present invention is to provide a method of producing each high purity imidazole dipeptide in large quantities on an industrial scale, regardless of the type of animal extract employed. The objective is achieved by a method of producing a purified imidazole dipeptide composition, including the step (1) of subjecting an animal extract treatment solution containing at least two types of imidazole dipeptides to adsorption treatment carried out by bringing the solution into contact with a hydrophobic adsorption resin to adsorb the imidazole dipeptides onto the hydrophobic adsorption resin; and the step (2) of subjecting the hydrophobic adsorption resin adsorbing the imidazole dipeptides to elution treatment using an aqueous solution to mutually separate and collect the imidazole dipeptides to purify an imidazole dipeptide.
PURIFICATION METHOD FOR IMIDAZOLE DIPEPTIDES
The objective of the present invention is to provide a method of producing each high purity imidazole dipeptide in large quantities on an industrial scale, regardless of the type of animal extract employed. The objective is achieved by a method of producing a purified imidazole dipeptide composition, including the step (1) of subjecting an animal extract treatment solution containing at least two types of imidazole dipeptides to adsorption treatment carried out by bringing the solution into contact with a hydrophobic adsorption resin to adsorb the imidazole dipeptides onto the hydrophobic adsorption resin; and the step (2) of subjecting the hydrophobic adsorption resin adsorbing the imidazole dipeptides to elution treatment using an aqueous solution to mutually separate and collect the imidazole dipeptides to purify an imidazole dipeptide.
Methods for purifying antibodies having reduced high molecular weight aggregates
Provided herein, in some embodiments, are methods and compositions for purifying antibodies from cellular cultures using one or more thiol containing additives during a purification process, for example in a chromatographic purification process.
Methods for purifying antibodies having reduced high molecular weight aggregates
Provided herein, in some embodiments, are methods and compositions for purifying antibodies from cellular cultures using one or more thiol containing additives during a purification process, for example in a chromatographic purification process.
USE OF NEUTRAL pH MOBILE PHASES IN REVERSED PHASE CHROMATOGRAPHY OF ACIDIC PEPTIDES
The present disclosure discusses a method of separating and/or purifying acidic peptides by the use of a mobile phase having a pH greater than or about equal to the isoelectric point of one or more of the metal oxides in the flow path.